Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food Effect on PA-111 Pharmacokinetics in Healthy Adults
NCT06976489Phase 1Not yet recruiting
- Sponsor
- Addpharma, Inc.
- Start
- May 2025
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of pitavastatin and ezetimibe in mixed dyslipidemia (2 arms), sponsored by Addpharma, Inc. Primary endpoints: Maximum concentration of drug in plasma at 72 hours and Area under the plasma concentration-time curve during dosing interval at 72 hours. Planned start May 2025; status: not yet recruiting.
02
Drugs
pitavastatinezetimibe
03
Conditions
mixed dyslipidemia
Beyond the preview
Go deeper on NCT06976489.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06976489.